
    
      The expected duration of study intervention for participants who benefit from study
      intervention may vary, based on progression date; but median expected duration of study per
      participant is estimated as median 9 months in docetaxel arm (1 month for screening, 4 months
      for treatment, and 4 months for the end of treatment and follow-up visits) and 12.5 months in
      SAR408701 arm (1 month for screening, 6.5 months for treatment, and 5 months for end of
      treatment follow-up).
    
  